The DUTCH Test and At-Home Hormone Tests: What They Measure and Where the Evidence Stands

Scroll through any perimenopause forum this month and you will meet the same image: a spreadsheet of colored bars, a dozen hormone names ending in “-diol” and “-one,” and a caption that reads “finally, answers.” The DUTCH test has become the shareable artifact of a wider moment. Hormone testing at home has moved from a niche practice to a mainstream search, pushed along by short videos in which practitioners read a stranger’s cortisol curve like a weather map. As of this writing in 2025, searches for the test sit at their highest point since it launched a decade ago.

The enthusiasm is understandable. Hot flashes, 3 a.m. waking, a fog that settles over the afternoon: these are real, and many people have been told their bloodwork is “normal” and sent home. A test that promises to explain the why is appealing.

So it is worth asking the quiet question behind the loud one. What does the panel actually measure, how good is the evidence that measuring it changes anything, and why do most endocrinologists and gynecologists still reach for a blood draw, or for no test at all?

What is the DUTCH test, exactly?

DUTCH stands for Dried Urine Test for Comprehensive Hormones. The name describes the method: you urinate on small filter-paper strips at several points over roughly 24 hours, let them dry, and mail them to the manufacturer’s laboratory. The lab rehydrates the samples and analyzes them with mass spectrometry, an instrument that identifies molecules by weight and can distinguish close chemical cousins from one another.

That last detail matters. Rather than reporting only estrogen, cortisol and testosterone, the panel reports their metabolites, which are the breakdown products the liver and other tissues produce as hormones are cleared from the body. A single hormone can appear as five or six lines on the report. The pitch is that these downstream molecules reveal how the body is processing hormones, not simply how much is circulating at one moment.

Several versions exist. The core sex-hormone and cortisol panel is often sold alongside a version that adds the cortisol awakening response, meaning cortisol measured on waking and again about 30 and 60 minutes later, and a version that adds organic acids, which are intermediate molecules from energy metabolism and neurotransmitter breakdown. Some kits combine dried urine with saliva for the cortisol portion.

Here is the frame to carry through everything that follows. A laboratory test has two separate layers of evidence. The first is analytical validity: does the machine reliably measure what it claims to measure? The second is clinical utility: does knowing that number lead to a decision that makes a person healthier than they would otherwise have been? Dried-urine hormone testing performs reasonably well on the first layer. The second is where the honest conversation begins.

What does a DUTCH test tell you? The panel, line by line

Open a report and the first page usually shows cortisol. There is a free cortisol curve, four or five points plotted from waking to bedtime, and a metabolized cortisol total, which estimates the full day’s output. The report also lists cortisone, the inactive form, and the ratio between the two, which the test presents as a window into how tissues switch cortisol on and off.

The sex-hormone pages come next. For estrogen, the report shows estrone, estradiol and estriol, the three main estrogens, then branches into how estrogen was processed. Three pathways are drawn: the 2-hydroxy route, which the report labels favorable; the 4-hydroxy route, labeled potentially harmful; and the 16-hydroxy route. A further step, methylation, which is the attachment of a small carbon group that helps the body excrete these molecules, is shown as a ratio.

Progesterone is reported indirectly, through two of its metabolites, since the hormone itself is poorly measured in urine. Testosterone and DHEA, an adrenal hormone that the body converts into both testosterone and estrogen, appear with their own metabolite trees, including a marker that suggests how actively testosterone is being converted to a more potent form.

Finally there is a page of small-molecule markers: melatonin’s main metabolite, a vitamin B12 marker, a B6 marker, markers of oxidative stress, and breakdown products of dopamine, norepinephrine and serotonin.

Everything above is a real molecule that a competent mass spectrometer can quantify. The interpretive language layered over it, the color coding and the words “favorable” or “harmful,” is where measurement ends and hypothesis begins. Keeping those two things apart is the single most useful skill for reading the report.

What changed recently

Three developments explain why the DUTCH test is trending now rather than five years ago.

First, the direction of mainstream guidance has become clearer, and it points away from testing. The National Institute for Health and Care Excellence in the United Kingdom updated its menopause guideline in November 2024, and the NHS patient guidance built on it still says the same thing it has since 2015: in women over 45 with typical symptoms, menopause and perimenopause are diagnosed from symptoms and age, and blood hormone tests are not usually needed. Mayo Clinic’s patient material takes an identical position and adds that follicle-stimulating hormone, the pituitary signal often used in blood tests, swings so much during perimenopause that one result can mislead. The gap between what guidelines say and what social media sells has widened, and that gap generates searches.

Second, the market for hormone testing at home has grown rapidly. Finger-prick, saliva and dried-urine kits now compete openly, and the DUTCH test has become the shorthand for the whole category in many conversations, much as one tissue brand stands in for all of them.

Third, perimenopause itself has become a cultural topic in a way it was not before. Celebrity disclosures, workplace policies and a surge of books have brought millions of women in their 40s into online spaces where this test circulates as a first recommendation.

What has not changed is the evidence base for using the metabolite patterns to guide treatment. No new randomized trial has appeared, and no professional society in endocrinology, gynecology or oncology has added dried-urine hormone metabolite testing to a clinical pathway. The trend is cultural and commercial, not a reflection of a scientific turn.

Dried urine vs blood, saliva and 24-hour urine: how the methods compare

Each sampling method captures a different slice of hormone biology, and none is simply better. The table below summarizes what the mainstream laboratory references describe.

Method	What it captures	Strengths	Limits
Blood (serum)	Circulating hormone at one moment	Decades of reference ranges; used in every guideline; diagnoses deficiency and excess states	Single snapshot; some hormones fluctuate hourly or by cycle day
Saliva	Free, unbound hormone at one moment	Easy repeated sampling; well studied for cortisol rhythm research	Reference ranges weaker for sex hormones; contamination with topical hormones distorts results
24-hour urine	Total daily hormone and metabolite output	Long clinical history, particularly for cortisol and adrenal disorders	Cumbersome collection; loses timing information
Dried urine (DUTCH)	Metabolites across four to five timed spots	Convenient; estimates daily output plus a daytime pattern	Proprietary ranges; metabolite interpretation not guideline-endorsed

MedlinePlus notes that a cortisol test may be performed on blood, saliva or urine depending on the question being asked, and that a 24-hour urine collection is a long-established way to estimate total daily cortisol. The dried-urine approach borrows that logic and simplifies collection. Published comparisons, several of them authored by scientists affiliated with the manufacturer, show reasonable agreement between dried-spot and full 24-hour urine for many analytes.

The important distinction is purpose. Blood testing exists to answer clinical questions with established thresholds: is cortisol too low, is testosterone deficient, is prolactin elevated. Dried-urine metabolite testing answers a different question, how hormones are being processed, and that question does not yet come with treatment thresholds anyone has validated.

What the evidence actually says, graded by strength

Grading evidence means asking what kind of study supports each claim. Here is how the main claims around the DUTCH test stack up.

Analytical validity: moderate. Peer-reviewed papers show that dried-urine mass spectrometry measures estrogens, androgens and cortisol metabolites with acceptable precision and correlates with 24-hour urine and, for some analytes, with serum. Most of this literature is small and much of it is company-affiliated, which is normal for a proprietary test but means independent replication is thin.

Cortisol rhythm as a research marker: moderate observational. Flattened daily cortisol slopes and blunted awakening responses have been associated in observational studies with chronic stress, depression and some cardiometabolic outcomes. These are population-level associations, and they have not been translated into individual treatment decisions.

Estrogen metabolite ratios and breast cancer risk: weak to mixed observational. Some cohort studies have linked a higher 2-hydroxy to 16-hydroxy ratio with lower risk; others found no association or the reverse. No trial has shown that shifting the ratio changes outcomes.

Diagnosing perimenopause or menopause: not supported. Guidelines from the NHS, NICE and Mayo Clinic rest on symptoms and age for women over 45, and no study shows urinary metabolites outperform that clinical approach.

Guiding hormone therapy decisions: no randomized evidence. There are no trials in which people randomized to DUTCH-guided care had fewer symptoms, fewer adverse events or better long-term outcomes than people receiving standard care.

“Adrenal fatigue”: expert consensus against. Endocrine societies state that adrenal fatigue is not a recognized medical diagnosis, and a systematic review of the studies behind it found no consistent cortisol signature.

The honest summary is that the test measures real things well, and that what those measurements mean for an individual’s care remains largely unproven.

Can the DUTCH test diagnose perimenopause or menopause?

Not in the way that word implies, and for a reason that has nothing to do with the quality of the laboratory.

Perimenopause is defined by a change in pattern over time: cycles that shorten, lengthen or skip, alongside symptoms such as hot flashes, night sweats, sleep disturbance and mood shifts. The NHS states plainly that for women over 45, perimenopause and menopause are diagnosed based on symptoms, without blood tests. Mayo Clinic agrees, noting that hormone testing is usually unnecessary and that follicle-stimulating hormone levels rise and fall unpredictably during the transition, so a single result can be falsely reassuring or falsely alarming.

That unpredictability is the crux. During perimenopause, estradiol can be higher than it was at 30 in one week and near postmenopausal levels the next. A test that samples one day, however thoroughly it samples that day, captures a single frame of a film with wild jump cuts. It can confirm that estrogen was low or high on the collection day. It cannot tell you where you are in a process whose defining feature is variability.

There are exceptions, and they are the cases where mainstream guidance does recommend testing. Women under 40 with menopausal symptoms may have premature ovarian insufficiency, and both NHS and Mayo Clinic advise blood testing in that group. Women between 40 and 45 with atypical presentations may also be tested. People who have had a hysterectomy without removal of the ovaries, or who use hormonal contraception that masks cycle changes, present genuine diagnostic puzzles. In each of these situations the recommended tool is a serum test ordered and interpreted by a clinician, because that is where the decision thresholds exist.

Cortisol, "adrenal fatigue" and the stress curve on your report

The cortisol page is often the part people find most striking, because it looks like a story. A line rises on waking, peaks, then slopes down toward bedtime, and the report shades a reference band around it. Cortisol is the body’s main stress and energy-regulating hormone, produced by the adrenal glands under direction from the brain’s hypothalamus and pituitary, a loop called the HPA axis.

Johns Hopkins describes two well-defined adrenal cortisol disorders. Addison’s disease involves adrenal glands that cannot produce enough cortisol, producing fatigue, weight loss, low blood pressure and skin darkening; it is dangerous and diagnosed with specific blood tests and stimulation testing. Cushing’s syndrome involves too much cortisol, from medication or a tumor, and is diagnosed with late-night saliva, 24-hour urine or suppression tests. Both conditions are uncommon, both are serious, and neither is diagnosed with a dried-urine wellness panel.

Between those extremes sits the concept most often attached to DUTCH results: adrenal fatigue, the idea that chronic stress exhausts the glands into underproduction. Cleveland Clinic’s patient material is direct about this: adrenal fatigue is not an accepted medical diagnosis, and the symptoms attributed to it, tiredness, sleep trouble, cravings, brain fog, overlap with depression, sleep apnea, iron deficiency, thyroid disease and ordinary overload. A systematic review of nearly 60 studies found no consistent cortisol pattern that identified the proposed condition.

What the curve can reasonably show is that daily rhythm exists and that it was, on one day, flatter or steeper than a reference population. That is interesting. It is also influenced by shift work, a bad night’s sleep, caffeine, exercise and the stress of collecting samples. Treating a single curve as a diagnosis, or as a reason to take supplements marketed for adrenal support, runs ahead of what the measurement can bear.

Estrogen metabolites and cancer risk: what the ratios can and cannot say

The most consequential claim attached to the DUTCH test is also the one that deserves the most care. The report presents three estrogen pathways and labels the 4-hydroxy route as potentially harmful because that metabolite can form reactive molecules capable of damaging DNA in laboratory conditions. From there it is a short step, often taken in online interpretations, to “your test shows you are at higher risk of breast cancer.”

The biology is real, and so is the gap between biology and prediction. The hypothesis that a higher proportion of 2-hydroxy metabolites protects against breast cancer dates to the 1990s. Cohort studies since then have been inconsistent. Some found modestly lower risk with a higher 2-to-16 ratio; a pooled analysis of several prospective studies found only a weak association in some groups and none in others; some found no relationship. The 4-hydroxy pathway has been studied less in humans, mostly in small case-control designs. None of this reaches the standard needed to tell an individual what their risk is.

Breast cancer risk assessment in clinical practice uses validated tools built on age, family history, breast density, prior biopsies and reproductive history, and in some families, genetic testing. Screening recommendations are based on age and these risk factors, not on urinary metabolites. No major cancer organization includes estrogen metabolite ratios in risk estimation.

The practical point for readers is this: a ratio flagged in red on a report is a hypothesis about biochemistry, not a risk score. If a result like this frightens you, the right next step is a conversation about validated risk assessment and appropriate screening for your age, not a supplement protocol aimed at moving a ratio whose clinical meaning is unsettled.

Hormone testing at home: what the other kits measure

The DUTCH test is one product in a crowded shelf, and the shelf is worth surveying, because the limitations differ by method.

Finger-prick blood kits are the closest to what a clinic orders. They typically measure estradiol, follicle-stimulating hormone, luteinizing hormone, testosterone, thyroid-stimulating hormone and sometimes prolactin or a long-acting marker of ovarian reserve. Because these are serum measurements, they can be compared against established laboratory ranges. The weakness is timing. MedlinePlus notes that estrogen testing in people who menstruate must be interpreted against cycle day, and a kit collected on the wrong day or during a perimenopausal swing produces a number without a context.

Saliva kits measure the free fraction of a hormone, the part not bound to carrier proteins. Saliva is well suited to tracking cortisol rhythm across a day and has a substantial research literature for that purpose. For sex hormones, saliva reference ranges are weaker, and anyone using a hormone cream or gel will see wildly inflated readings from contamination of the mouth and skin.

Dried-urine kits, including the DUTCH test, offer metabolite detail that neither blood nor saliva provides, at the price of interpretive uncertainty described throughout this article.

A few points apply across every category. Results are not reviewed by a clinician who knows your history unless you bring them to one. Reference ranges in direct-to-consumer kits may not match those used by hospital laboratories. A normal result does not rule out a medical cause for symptoms, and an abnormal one does not establish one. Hormone testing at home works best as a conversation starter with a clinician, not as a substitute for the appointment.

Why don't doctors use the DUTCH test?

This is one of the most searched questions about the test, and the answer is less about resistance than about how medicine decides which tests earn a place in care.

Clinicians order tests that change decisions. For a woman over 45 with hot flashes and irregular cycles, guidelines say the diagnosis is clinical and the treatment conversation can begin without any test. If menopausal hormone therapy is prescribed, Mayo Clinic and NHS guidance describe adjusting it based on symptom relief and side effects, not on laboratory targets. A metabolite panel does not alter that pathway, so most gynecologists have no decision for it to inform.

Endocrinologists have a related reason. The disorders they diagnose, from Addison’s disease to polycystic ovary syndrome, have defined diagnostic criteria built on specific serum tests with validated thresholds. A dried-urine panel with proprietary reference ranges cannot substitute for those criteria, and an abnormal urinary result would still require the standard blood work to confirm or exclude disease.

There is also the question of what to do with the information. If a report says estrogen methylation is “slow,” the interventions offered in wellness settings are typically supplements and diet changes whose effect on the ratio, and on any outcome that matters, has not been demonstrated in trials. Physicians trained to avoid treating numbers without evidence of benefit are appropriately reluctant.

Finally, the test is not covered by most insurers and is not included in any professional society guideline, which places it outside the normal ordering infrastructure of a clinic.

None of this means the test is fraudulent. It means it sits in the space between an interesting research method and an established clinical tool, and conventional medicine is cautious about that space by design.

Is a DUTCH test worth it, and will insurance pay?

Insurance first, because the answer is simple. In the United States, most health plans classify the DUTCH test as not medically necessary, since no guideline recommends it, and most people pay out of pocket. Some flexible spending or health savings accounts may reimburse laboratory tests ordered by a licensed practitioner; the rules vary, and the plan administrator is the only reliable source. Public systems such as the NHS do not offer it.

“Worth it” is a harder question because it depends on what you expect to receive. If the goal is to confirm perimenopause, the evidence reviewed above says the test cannot do that better than a conversation with a clinician, and may muddy the picture. If the goal is to diagnose an adrenal disorder, thyroid disease or a pituitary problem, a dried-urine panel is the wrong tool and may delay the right one. If the goal is to decide whether to start or adjust menopausal hormone therapy, guidelines base that decision on symptoms, medical history and personal preference, with no laboratory target to hit.

Where the test has a more defensible role is narrower. Researchers use metabolite and rhythm data to study stress physiology at the population level. Some clinicians who prescribe hormone therapy want to see that a transdermal or oral product is being absorbed and processed, and a metabolite panel can show that, although serum testing can too. People who simply want to see a detailed picture of their own biochemistry for curiosity’s sake are entitled to that, provided they understand the picture comes without a validated instruction manual.

A useful test before buying is to ask: what decision will I make differently depending on the result? If the honest answer is “none, but I would feel reassured,” remember that the reassurance may be false in either direction.

Common myths about the DUTCH test, corrected

Viral explanations travel faster than footnotes. Here are the claims that circulate most often, set against what the evidence supports.

Myth: “Blood tests are useless for hormones; only DUTCH shows the real picture.” Blood testing is the foundation of every endocrine diagnosis and every guideline. It has limits, chiefly timing, but it is far from useless. Dried urine adds metabolite detail; it does not replace serum.

Myth: “The test diagnosed my adrenal fatigue.” Cleveland Clinic and endocrine societies are clear that adrenal fatigue is not a recognized diagnosis. True adrenal insufficiency is diagnosed with specific blood and stimulation tests and is a medical emergency when severe.

Myth: “My estrogen metabolite ratio means I’m heading for breast cancer.” Observational studies of these ratios are mixed, and no cancer organization uses them for risk assessment. Validated risk tools and age-based screening remain the standard.

Myth: “Estrogen dominance is a diagnosis the test confirms.” The phrase describes a relative pattern, not a medical condition with agreed criteria. Estrogen and progesterone shift constantly in perimenopause, and a single day’s ratio does not define a disorder.

Myth: “You need the test before starting hormone therapy.” NHS and Mayo Clinic guidance describes starting and adjusting menopausal hormone therapy according to symptoms and medical history, without baseline metabolite testing.

Myth: “A normal DUTCH result means my symptoms aren’t hormonal, or aren’t medical.” A normal result rules out very little. Fatigue, mood change and sleep disruption have many causes that this panel does not assess, including thyroid disease, anemia, depression and sleep apnea.

The pattern across these myths is the same: a real measurement is upgraded into a diagnosis or a prediction that the evidence has not earned.

How to read a DUTCH test result without overreacting

If you have already taken the test, or someone close to you has, the report is now a fact in your life, and there is a sensible way to hold it.

Start by sorting the pages into two piles. The first pile contains measurements that mainstream medicine also uses and can act on: cortisol output that is strikingly low or high across the whole day, testosterone that is well outside normal, or markers of a vitamin deficiency. These are worth raising with a clinician, who will almost always want to confirm them with a standard blood test before acting, because that is where the decision thresholds live.

The second pile contains the interpretive layer: pathway preferences, methylation ratios, “favorable” and “unfavorable” labels, and the small-molecule neurotransmitter markers. These describe biochemistry whose clinical meaning has not been established in trials. Treat this pile as interesting, not as instructions.

Then consider the day you collected. Shift work, a poor night’s sleep, illness, intense exercise, alcohol, a stressful week or a hormonal contraceptive all shape the result. If you use any hormone cream or gel, contamination can distort estrogen and progesterone values dramatically. The report is a portrait of one specific day under specific conditions.

Be wary of anyone who moves directly from your report to a list of supplements, especially products marketed for adrenal support, estrogen detoxification or methylation. The evidence that these shift the measured ratios is thin, and the evidence that shifting them improves health is absent.

Above all, bring the report to the clinician who manages your care, including whoever prescribes any hormone therapy you use. Never stop, start or change a prescribed medicine on the strength of a wellness panel. That decision belongs with the prescriber, informed by your symptoms and your full history.

When to see a doctor

Hormone symptoms are common and most are not dangerous, but some patterns need a clinician rather than a kit, and some need one quickly.

Arrange an appointment soon if you have menopausal symptoms before age 40, since premature ovarian insufficiency affects bone, heart and long-term health and is diagnosed with blood tests, not symptoms alone. See a doctor if bleeding is very heavy, lasts longer than a week, occurs between periods or returns after a year or more without periods; postmenopausal bleeding always requires evaluation. Book a visit for new facial hair growth, deepening voice or scalp hair loss, for persistent fatigue with unexplained weight change, or for a low mood that interferes with daily life. If you are already on hormone therapy and your symptoms have changed, or a test result worries you, the prescriber is the right person to interpret it.

Seek urgent care, or emergency services, for the following red flags:

• Fainting, severe dizziness on standing, vomiting and profound weakness, particularly with darkening skin or salt craving, which can signal an adrenal crisis.
• A new breast lump, skin dimpling, nipple discharge or change in breast shape.
• Chest pain, sudden breathlessness, or pain and swelling in one calf, especially while using estrogen-containing therapy, which can indicate a blood clot.
• Sudden severe headache, vision loss or weakness on one side of the body.
• Thoughts of self-harm alongside mood changes.

Any result from the DUTCH test or any at-home hormone kit, whether reassuring or alarming, should be reviewed by a clinician who knows your history. They may repeat key measurements with standard blood tests, ask about sleep, iron and thyroid function, or simply confirm that your symptoms fit a well-understood life stage that can be managed without further testing.

Frequently asked questions

What does a DUTCH test tell you?

A DUTCH test reports levels of cortisol, estrogens, progesterone metabolites, testosterone and DHEA, plus the breakdown products of each, measured from dried urine collected at several points across one day. It also plots a daily cortisol curve and includes markers for melatonin, some B vitamins and neurotransmitter metabolites. It shows how hormones were processed on the collection day; it does not diagnose menopause, adrenal disorders or cancer risk.

Will insurance pay for a DUTCH test?

Usually not. Most US health plans consider the test not medically necessary because no clinical guideline recommends it, so people typically pay out of pocket. Some health savings or flexible spending accounts may reimburse laboratory tests ordered by a licensed practitioner, but rules differ by plan, so check with your administrator. Public health systems such as the NHS do not provide it.

Is a DUTCH hormone test worth the money?

It depends on the decision you expect it to inform. For confirming perimenopause, deciding on hormone therapy or diagnosing a medical condition, guidelines rely on symptoms and standard blood tests, so the panel adds little. It can show how hormones are being metabolized, which some people find informative, but no trial shows that acting on those patterns improves health. Ask what you would do differently based on the result.

Why don't doctors use DUTCH tests?

Because the test does not change the decisions most clinicians make. Menopause is diagnosed clinically in women over 45, hormone therapy is adjusted by symptoms rather than laboratory targets, and endocrine disorders have defined blood-test criteria that a dried-urine panel cannot replace. The test also uses proprietary reference ranges, lacks outcome trials and is not in any professional society guideline.

Can hormone testing at home diagnose perimenopause?

No. Perimenopause is defined by changing cycle patterns and symptoms over time, and hormone levels swing widely from week to week during the transition. A single-day kit, whether blood, saliva or dried urine, captures one frame of a highly variable process. NHS and Mayo Clinic guidance says women over 45 with typical symptoms do not need hormone testing; those under 40 should see a doctor for blood tests.

Is the DUTCH test accurate?

Its laboratory methods appear analytically sound. Published studies show dried-urine mass spectrometry measures hormone metabolites with acceptable precision and correlates reasonably with 24-hour urine collections, though much of that research is small and company-affiliated. Accuracy of measurement is separate from clinical usefulness, and the interpretive labels on the report, such as favorable or harmful pathways, have not been validated to guide treatment.

Does the DUTCH test show adrenal fatigue?

Adrenal fatigue is not a recognized medical diagnosis, so no test can show it. The DUTCH report does plot a daily cortisol pattern, which can look flatter or steeper than a reference range, but that pattern is shaped by sleep, shift work, caffeine and stress on the collection day. Genuine adrenal insufficiency is a serious condition diagnosed with specific blood and stimulation tests ordered by a clinician.

Can the DUTCH test predict breast cancer risk?

No. The report shows the proportion of estrogen processed through different pathways, and laboratory research suggests one pathway can produce DNA-reactive molecules. Human cohort studies linking these ratios to breast cancer are inconsistent, and no cancer organization uses them in risk assessment. Validated risk tools based on age, family history and breast density, combined with age-appropriate screening, remain the standard.

Should I take a DUTCH test before starting hormone therapy?

Guidelines do not call for it. NHS and Mayo Clinic describe starting menopausal hormone therapy based on symptoms, age and medical history, then adjusting according to symptom relief and side effects rather than laboratory targets. Blood tests may be ordered in specific situations, such as symptoms before age 45. Whether any test is useful in your case is a decision for the prescribing clinician.

What is the difference between a dried urine hormone test and a blood test?

A blood test measures hormone circulating at one moment and is compared against decades of established reference ranges and diagnostic thresholds. A dried-urine test measures metabolites, the breakdown products, across several timed samples, estimating daily output and processing patterns. Blood is the standard for diagnosing deficiency and excess states; dried urine offers extra biochemical detail whose clinical meaning is less settled.

References

• MedlinePlus: Cortisol Test
• MedlinePlus: Estrogen Levels Test
• Cleveland Clinic: Cortisol

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.